GABELLI FUNDS LLC - TETRAPHASE PHARMACEUTICALS I ownership

TETRAPHASE PHARMACEUTICALS I's ticker is TTPHXXXX and the CUSIP is 88165N105. A total of 139 filers reported holding TETRAPHASE PHARMACEUTICALS I in Q2 2015. The put-call ratio across all filers is 0.85 and the average weighting 0.1%.

Quarter-by-quarter ownership
GABELLI FUNDS LLC ownership history of TETRAPHASE PHARMACEUTICALS I
ValueSharesWeighting
Q2 2019$14,000
-87.3%
30,000
-63.4%
0.00%
-100.0%
Q1 2019$110,000
-0.9%
82,000
-16.3%
0.00%0.0%
Q4 2018$111,000
-58.1%
98,000
+2.1%
0.00%
-50.0%
Q3 2018$265,000
-39.2%
96,000
-21.3%
0.00%
-33.3%
Q2 2018$436,000
+14.4%
122,000
-1.6%
0.00%
+50.0%
Q1 2018$381,000
-51.2%
124,0000.0%0.00%
-50.0%
Q4 2017$781,000
-10.8%
124,000
-3.1%
0.00%
-20.0%
Q3 2017$876,000
-4.1%
128,0000.0%0.01%0.0%
Q2 2017$913,000
-22.4%
128,0000.0%0.01%
-28.6%
Q1 2017$1,176,000
+127.9%
128,0000.0%0.01%
+133.3%
Q4 2016$516,000
+5.3%
128,0000.0%0.00%0.0%
Q3 2016$490,000
-5.0%
128,000
+6.7%
0.00%0.0%
Q2 2016$516,000
+89.0%
120,000
+103.4%
0.00%
+50.0%
Q1 2016$273,000
-45.6%
59,000
+18.0%
0.00%
-33.3%
Q4 2015$502,000
+34.6%
50,0000.0%0.00%
+50.0%
Q3 2015$373,000
-94.6%
50,000
-65.8%
0.00%
-94.4%
Q2 2015$6,926,000
-28.7%
146,000
-44.9%
0.04%
-26.5%
Q1 2015$9,709,000
+288.0%
264,990
+320.6%
0.05%
+308.3%
Q4 2014$2,502,000
+62.9%
63,000
-18.2%
0.01%
+50.0%
Q3 2014$1,536,000
+184.4%
77,000
+92.5%
0.01%
+166.7%
Q2 2014$540,00040,0000.00%
Other shareholders
TETRAPHASE PHARMACEUTICALS I shareholders Q2 2015
NameSharesValueWeighting ↓
HARVEY CAPITAL MANAGEMENT INC 293,675$14,061,0004.76%
BB BIOTECH AG 1,507,114$71,497,0001.94%
SECTORAL ASSET MANAGEMENT INC 893,076$42,368,0001.77%
Opaleye Management Inc. 65,000$3,084,0001.23%
COLUMBIA PARTNERS L.L.C. INVESTMENT MANAGEMENT 390,294$18,515,0001.14%
Granite Point Capital Management, L.P. 75,206$3,568,0001.04%
Granahan Investment Management 705,601$33,474,0000.95%
Iguana Healthcare Management, LLC 50,000$2,372,0000.75%
Eventide Asset Management 290,000$13,758,0000.74%
Rhenman & Partners Asset Management AB 107,400$5,095,0000.61%
View complete list of TETRAPHASE PHARMACEUTICALS I shareholders